BEAM Quote, Financials, Valuation and Earnings

Intellia Therapeutics, Inc. has a net margin of -1162.38% compared to Beam Therapeutics, Inc.'s net margin of -735.19%. Beam Therapeutics, Inc.'s return on equity of -44.48% beat Intellia Therapeutics, Inc.'s return on equity of -54.66%.

Beam Therapeutics, Inc. has a consensus price target of $47.21, signalling upside risk potential of 69.35%. On the other hand Intellia Therapeutics, Inc. has an analysts' consensus of $23.86 which suggests that it could grow by 82.95%. Given that Intellia Therapeutics, Inc. has higher upside potential than Beam Therapeutics, Inc., analysts believe Intellia Therapeutics, Inc. is more attractive than Beam Therapeutics, Inc..

Beam Therapeutics, Inc. has a beta of 2.116, which suggesting that the stock is 111.58% more volatile than S&P 500. In comparison Intellia Therapeutics, Inc. has a beta of 2.103, suggesting its more volatile than the S&P 500 by 110.271%.

Beam Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beam Therapeutics, Inc. pays -- of its earnings as a dividend. Intellia Therapeutics, Inc. pays out -- of its earnings as a dividend.

Beam Therapeutics, Inc. quarterly revenues are $9.7M, which are smaller than Intellia Therapeutics, Inc. quarterly revenues of $13.8M. Beam Therapeutics, Inc.'s net income of -$112.7M is lower than Intellia Therapeutics, Inc.'s net income of -$101.3M. Notably, Beam Therapeutics, Inc.'s price-to-earnings ratio is -- while Intellia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beam Therapeutics, Inc. is 46.97x versus 23.76x for Intellia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pacific Biosciences of California, Inc. has a net margin of -1162.38% compared to Beam Therapeutics, Inc.'s net margin of -90.43%. Beam Therapeutics, Inc.'s return on equity of -44.48% beat Pacific Biosciences of California, Inc.'s return on equity of -389.62%.

Beam Therapeutics, Inc. has a consensus price target of $47.21, signalling upside risk potential of 69.35%. On the other hand Pacific Biosciences of California, Inc. has an analysts' consensus of $2.50 which suggests that it could grow by 48.81%. Given that Beam Therapeutics, Inc. has higher upside potential than Pacific Biosciences of California, Inc., analysts believe Beam Therapeutics, Inc. is more attractive than Pacific Biosciences of California, Inc..

Beam Therapeutics, Inc. has a beta of 2.116, which suggesting that the stock is 111.58% more volatile than S&P 500. In comparison Pacific Biosciences of California, Inc. has a beta of 2.267, suggesting its more volatile than the S&P 500 by 126.686%.

Beam Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pacific Biosciences of California, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beam Therapeutics, Inc. pays -- of its earnings as a dividend. Pacific Biosciences of California, Inc. pays out -- of its earnings as a dividend.

Beam Therapeutics, Inc. quarterly revenues are $9.7M, which are smaller than Pacific Biosciences of California, Inc. quarterly revenues of $44.6M. Beam Therapeutics, Inc.'s net income of -$112.7M is lower than Pacific Biosciences of California, Inc.'s net income of -$40.4M. Notably, Beam Therapeutics, Inc.'s price-to-earnings ratio is -- while Pacific Biosciences of California, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beam Therapeutics, Inc. is 46.97x versus 3.15x for Pacific Biosciences of California, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -1162.38% compared to Beam Therapeutics, Inc.'s net margin of 21.74%. Beam Therapeutics, Inc.'s return on equity of -44.48% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Beam Therapeutics, Inc. has a consensus price target of $47.21, signalling upside risk potential of 69.35%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $868.04 which suggests that it could grow by 10.95%. Given that Beam Therapeutics, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Beam Therapeutics, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Beam Therapeutics, Inc. has a beta of 2.116, which suggesting that the stock is 111.58% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.

Beam Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.94 per share. Beam Therapeutics, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Beam Therapeutics, Inc. quarterly revenues are $9.7M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Beam Therapeutics, Inc.'s net income of -$112.7M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Beam Therapeutics, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beam Therapeutics, Inc. is 46.97x versus 5.93x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Twist Bioscience Corp. has a net margin of -1162.38% compared to Beam Therapeutics, Inc.'s net margin of -29.42%. Beam Therapeutics, Inc.'s return on equity of -44.48% beat Twist Bioscience Corp.'s return on equity of -16.63%.

Beam Therapeutics, Inc. has a consensus price target of $47.21, signalling upside risk potential of 69.35%. On the other hand Twist Bioscience Corp. has an analysts' consensus of $49.89 which suggests that it could fall by -4.96%. Given that Beam Therapeutics, Inc. has higher upside potential than Twist Bioscience Corp., analysts believe Beam Therapeutics, Inc. is more attractive than Twist Bioscience Corp..

Beam Therapeutics, Inc. has a beta of 2.116, which suggesting that the stock is 111.58% more volatile than S&P 500. In comparison Twist Bioscience Corp. has a beta of 2.240, suggesting its more volatile than the S&P 500 by 124.046%.

Beam Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Twist Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Beam Therapeutics, Inc. pays -- of its earnings as a dividend. Twist Bioscience Corp. pays out -- of its earnings as a dividend.

Beam Therapeutics, Inc. quarterly revenues are $9.7M, which are smaller than Twist Bioscience Corp. quarterly revenues of $103.7M. Beam Therapeutics, Inc.'s net income of -$112.7M is lower than Twist Bioscience Corp.'s net income of -$30.5M. Notably, Beam Therapeutics, Inc.'s price-to-earnings ratio is -- while Twist Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Beam Therapeutics, Inc. is 46.97x versus 8.12x for Twist Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.